Novavax | NVAX - Current Liabilities


Novavax reported $330.57M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Adma Biologics USD 75.76M 2.22M Jun/2026
Agenus USD 231.82M 17.42M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
BioCryst Pharmaceuticals USD 208.85M 13.46M Jun/2026
Cassava Sciences USD 40.11M 3.72M Mar/2026
Geron USD 70.33M 3.24M Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
MannKind USD 142.9M 8.34M Jun/2026
Merck USD 27.73B 786M Jun/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Moderna USD 2.53B 139M Jun/2026
Novartis USD 31.37B 4.1B Mar/2026
Novavax USD 330.57M 11.89M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
TG Therapeutics USD 268.49M 81.38M Jun/2026